Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY-NC-ND 4.0BMC Endocrine Disorders

Incidence, prevalence, and ketoacidosis at onset of type 1 diabetes in Spain: a systematic review and critical assessment of the available evidence

13 affiliations
  1. 1Pharmacoeconomics & Outcomes Research Iberia (PORIB), Paseo Joaquín Rodrigo 4-Letter I, Madrid, 28224 Spain
  2. 2Endocrinology and Nutrition Department, Hospital Clínico Universitario de Valencia, Valencia, Spain
  3. 3Medicine Faculty, University of Valencia, Valencia, Spain
  4. 4Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
  5. 5INCLIVA Biomedical Research Institute, Valencia, Spain
  6. 6Pediatric Department, Pediatric Endocrinology. Hospital Clínico Universitario de Valladolid, Valladolid, Spain
  7. 7Instituto de Investigación Biosanitaria de Valladolid (IBioVall), Valladolid, Spain
  8. 8Hospital Universitario Cruces, Biobizkaia, País Vasco, Spain
  9. 9Universidad del País Vasco EHU, País Vasco, Spain
  10. 10Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) y enfermedades raras (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
  11. 11European Reference Network on Endocrine Conditions (Endo-ERN), Amsterdam, The Netherlands
  12. 12Health Economics & Pricing Business Partner, Market Access, Sanofi, Madrid, Spain
  13. 13Health Economics & Outcomes Research and Pricing and Contracting Lead, Market Access, Sanofi, Barcelona, Spain

Abstract

Background: The incidence, prevalence and onset of type 1 diabetes (T1D) with diabetic ketoacidosis (DKA) in Spain remain insufficiently characterized, despite multiple regional analyses. This study aims to summarize and critically assess epidemiologic data in Spain, incorporating insights from the clinician authors, considering clinically diagnosed T1D (stage 3).

Methods: A systematic literature review of PubMed and Embase was conducted to identify available epidemiological evidence in Spain. Subsequently, nominal group techniques were applied to gather qualitative insights on methodological issues of the sources and estimates for the incidence, prevalence and onset of T1D with DKA.

Results: Of the 528 references identified and screened, 61 met eligibility criteria and were evaluated by clinician authors within the nominal group. Methodological insights suggested a meta-analysis to be the most robust source for pediatric incidence (incidence rate [IR]: 17.04 cases/100,000 inhabitants <15 years), complemented by an observational study using the capture-recapture method in Navarre (IRs per 100,000 inhabitants-years: 14.99 [<15 years], 15.8 [15-29 years], 7.6 [30-45 years], and 2.2 [≥45 years]). The most reliable prevalence estimates indicated rates of 1.01-1.44/1,000 inhabitants in pediatric populations, increasing to 9.0/1,000 inhabitants in adults. Onset of T1D with DKA showed highest frequency in individuals <15 years (36.0-48.0%), decreasing progressively with age: 26.1% (15-29 years), 19.2% (30-44 years), and 12.3% (≥45 years). A potential underestimation was highlighted for failing to account for their upward trend over time, the model-based estimates for people <15 years presented in the 11th Edition of the International Diabetes Federation Atlas being a potential alternative for both IR (24.1 cases/100,000 inhabitants <15 years) and prevalence (1.58 cases/1,000 inhabitants <15 years).

Conclusion: This study synthesized and identified the most robust evidence available regarding the incidence, prevalence and onset of T1D with DKA in Spain. The findings highlight substantial heterogeneity across regions and emphasize the need for more comprehensive and standardized epidemiological research.

Trial registration: Not applicable.

Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12902-026-02443-3.

Related

  1. Incidence and prevalence of hidradenitis suppurativa across spondyloarthritis-related diseases: cohort study using electronic health records
    Sizheng Steven Zhao, Qingfan Yang, Zhimin Liu +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyCrossrefEurope PMCPMC
  2. Prevalence and incidence of non-communicable diseases among older adults living with HIV on antiretroviral therapy in Northern Haiti: A retrospective cohort study
    Ronald Thiersaint, Romaine Nephtalie Mésidor, Valérie Pelletier +7
    PLOS Global Public HealthPeer-reviewedCC BY 4.0Full textImmunologyMicrobiologyPLOS
  3. Long COVID prevalence among U.S. adults: A state-level ecological analysis of associations with SARS-CoV-2 incidence, COVID-19 hospitalization rates, COVID-19 vaccine coverage, and multimorbidity
    Xinmeng Zhao, Li Deng, Nicole D. Ford +1
    PLOS OnePeer-reviewedCC0Full textImmunologyMicrobiologyPLOSPMC
  4. Incidence, prevalence, mortality and survival trends in women with endometrial-, ovarian- and cervical cancer in the Nordic countries (1980–2023) with focus on younger women (0–49 years old)
    Charlotta Riese, Enoch Yi-Tung, Hanna Nilsson +8
    Gynecologic OncologyPeer-reviewedCC BY1 citedGeneral biologyEpidemiology & public healthHAL
  5. Opisthorchis viverrini Control and Cholangiocarcinoma Incidence in Thailand: A Systematic Narrative Review and Proposed Interrupted Time Series Design
    Marcus Webb
    Zenodo (CERN European Organization for Nuclear Research)PreprintPublic domain8 citedMicrobiologyOpenAlex
BibTeX
@article{roblesplaza2026incidence,
  title = {{Incidence, prevalence, and ketoacidosis at onset of type 1 diabetes in Spain: a systematic review and critical assessment of the available evidence}},
  author = {Mireya Robles-Plaza and Francisco Javier Ampudia-Blasco and María Pilar Bahíllo Curieses and Luis Castaño and Jordi Aparici Espot and Juan Luis López-Belmonte and Itziar Oyagüez and Alberto de la Cuadra-Grande},
  journal = {BMC Endocrine Disorders},
  year = {2026},
  month = aug,
  doi = {10.1186/s12902-026-02443-3},
  url = {https://doi.org/10.1186/s12902-026-02443-3},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Incidence, prevalence, and ketoacidosis at onset of type 1 diabetes in Spain: a systematic review and critical assessment of the available evidence
AU  - Mireya Robles-Plaza
AU  - Francisco Javier Ampudia-Blasco
AU  - María Pilar Bahíllo Curieses
AU  - Luis Castaño
AU  - Jordi Aparici Espot
AU  - Juan Luis López-Belmonte
AU  - Itziar Oyagüez
AU  - Alberto de la Cuadra-Grande
PY  - 2026
DA  - 2026/08/17
JO  - BMC Endocrine Disorders
DO  - 10.1186/s12902-026-02443-3
UR  - https://doi.org/10.1186/s12902-026-02443-3
AB  - Background: The incidence, prevalence and onset of type 1 diabetes (T1D) with diabetic ketoacidosis (DKA) in Spain remain insufficiently characterized, despite multiple regional analyses. This study aims to summarize and critically assess epidemiologic data in Spain, incorporating insights from the clinician authors, considering clinically diagnosed T1D (stage 3).  Methods: A systematic literature review of PubMed and Embase was conducted to identify available epidemiological evidence in Spain. Subsequently, nominal group techniques were applied to gather qualitative insights on methodological issues of the sources and estimates for the incidence, prevalence and onset of T1D with DKA.  Results: Of the 528 references identified and screened, 61 met eligibility criteria and were evaluated by clinician authors within the nominal group. Methodological insights suggested a meta-analysis to be the most robust source for pediatric incidence (incidence rate [IR]: 17.04 cases/100,000 inhabitants <15 years), complemented by an observational study using the capture-recapture method in Navarre (IRs per 100,000 inhabitants-years: 14.99 [<15 years], 15.8 [15-29 years], 7.6 [30-45 years], and 2.2 [≥45 years]). The most reliable prevalence estimates indicated rates of 1.01-1.44/1,000 inhabitants in pediatric populations, increasing to 9.0/1,000 inhabitants in adults. Onset of T1D with DKA showed highest frequency in individuals <15 years (36.0-48.0%), decreasing progressively with age: 26.1% (15-29 years), 19.2% (30-44 years), and 12.3% (≥45 years). A potential underestimation was highlighted for failing to account for their upward trend over time, the model-based estimates for people <15 years presented in the 11th Edition of the International Diabetes Federation Atlas being a potential alternative for both IR (24.1 cases/100,000 inhabitants <15 years) and prevalence (1.58 cases/1,000 inhabitants <15 years).  Conclusion: This study synthesized and identified the most robust evidence available regarding the incidence, prevalence and onset of T1D with DKA in Spain. The findings highlight substantial heterogeneity across regions and emphasize the need for more comprehensive and standardized epidemiological research.  Trial registration: Not applicable.  Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1186/s12902-026-02443-3.
SN  - 1472-6823
ER  -